This special issue of CURE Lung Cancer takes a deeper dive into ALK-positive non-small cell lung cancer. In this special issue of CURE, we examine some of the latest developments in the treatment of ...

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors ...

A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC). Prior ...

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive ...

A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...

CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectively In the ...